4ZTH
Structure of human p38aMAPK-arylpyridazinylpyridine fragment complex used in inhibitor discovery
4ZTH の概要
| エントリーDOI | 10.2210/pdb4zth/pdb |
| 分子名称 | Mitogen-activated protein kinase 14, 6-chloro-3-phenyl-4-(pyridin-4-yl)pyridazine, 4-[3-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL]PYRIDINE, ... (5 entities in total) |
| 機能のキーワード | transferase |
| 由来する生物種 | Homo sapiens (Human) |
| タンパク質・核酸の鎖数 | 1 |
| 化学式量合計 | 44541.00 |
| 構造登録者 | |
| 主引用文献 | Roy, S.M.,Minasov, G.,Arancio, O.,Chico, L.W.,Van Eldik, L.J.,Anderson, W.F.,Pelletier, J.C.,Watterson, D.M. A Selective and Brain Penetrant p38 alpha MAPK Inhibitor Candidate for Neurologic and Neuropsychiatric Disorders That Attenuates Neuroinflammation and Cognitive Dysfunction. J.Med.Chem., 62:5298-5311, 2019 Cited by PubMed Abstract: The p38αMAPK is a serine/threonine protein kinase and a key node in the intracellular signaling networks that transduce and amplify stress signals into physiological changes. A preponderance of preclinical data and clinical observations established p38αMAPK as a brain drug discovery target involved in neuroinflammatory responses and synaptic dysfunction in multiple degenerative and neuropsychiatric brain disorders. We summarize the discovery of highly selective, brain-penetrant, small molecule p38αMAPK inhibitors that are efficacious in diverse animal models of neurologic disorders. A crystallography and pharmacoinformatic approach to fragment expansion enabled the discovery of an efficacious hit. The addition of secondary pharmacology screens to refinement delivered lead compounds with improved selectivity, appropriate pharmacodynamics, and efficacy. Safety considerations and additional secondary pharmacology screens drove optimization that delivered the drug candidate MW01-18-150SRM (MW150), currently in early stage clinical trials. PubMed: 30978288DOI: 10.1021/acs.jmedchem.9b00058 主引用文献が同じPDBエントリー |
| 実験手法 | X-RAY DIFFRACTION (2.15 Å) |
構造検証レポート
検証レポート(詳細版)
をダウンロード
をダウンロード
